Abstract
Thrombospondin-1 (TSP-1) was one of the first endogenous inhibitors of angiogenesis to be discovered. This large multimodular protein of around 600 kDa inhibits endothelial cell proliferation, migration and morphogenic organization into capillary tubes. TSP-2 shares homology with TSP-1 in primary sequence, structural organization and angiostatic properties. TSP-1-null and TSP-2-null mice display increased tissue vascularity and enhanced sensitivity to carcinogenesis. Conversely, overexpression of TSP-1 or TSP-2 in cancer cells results in reduced tumor vascularization and tumor growth. In this review, we focus on the preclinical data obtained in experimental anti-tumorigenic assays using either TSP-1, TSP-2 or shorter peptides derived from the type 1 repeats of these molecules. In contrast with the full length thrombospondin molecules, which present a poor bioavailability and are highly susceptible to proteolytic degradation, TSP-derived angiostatic peptides appear as potent and promising therapeutic agents in anti-angiogenic therapy.
Keywords: angiogenesis, thrombospondins, angiogenesis inhibition, angiostatic therapy, cancer.
Current Pharmaceutical Design
Title: Thrombospondins as Anti-Angiogenic Therapeutic Agents
Volume: 9 Issue: 7
Author(s): Bruno Vailhé and Jean-Jacques Feige
Affiliation:
Keywords: angiogenesis, thrombospondins, angiogenesis inhibition, angiostatic therapy, cancer.
Abstract: Thrombospondin-1 (TSP-1) was one of the first endogenous inhibitors of angiogenesis to be discovered. This large multimodular protein of around 600 kDa inhibits endothelial cell proliferation, migration and morphogenic organization into capillary tubes. TSP-2 shares homology with TSP-1 in primary sequence, structural organization and angiostatic properties. TSP-1-null and TSP-2-null mice display increased tissue vascularity and enhanced sensitivity to carcinogenesis. Conversely, overexpression of TSP-1 or TSP-2 in cancer cells results in reduced tumor vascularization and tumor growth. In this review, we focus on the preclinical data obtained in experimental anti-tumorigenic assays using either TSP-1, TSP-2 or shorter peptides derived from the type 1 repeats of these molecules. In contrast with the full length thrombospondin molecules, which present a poor bioavailability and are highly susceptible to proteolytic degradation, TSP-derived angiostatic peptides appear as potent and promising therapeutic agents in anti-angiogenic therapy.
Export Options
About this article
Cite this article as:
Vailhé Bruno and Feige Jean-Jacques, Thrombospondins as Anti-Angiogenic Therapeutic Agents, Current Pharmaceutical Design 2003; 9 (7) . https://dx.doi.org/10.2174/1381612033391342
DOI https://dx.doi.org/10.2174/1381612033391342 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence
Current Pharmaceutical Design Stem Cells and the Side Population Theory: A Critical Review
Current Tissue Engineering (Discontinued) Double Edge Sword Behavior of Carbendazim: A Potent Fungicide With Anticancer Therapeutic Properties
Anti-Cancer Agents in Medicinal Chemistry HIF-1α Modulates Energy Metabolism in Cancer Cells by Inducing Over-Expression of Specific Glycolytic Isoforms
Mini-Reviews in Medicinal Chemistry Data Mining of Differentially Expressed Genes in Ovarian Epithelial Carcinoma: Implications in Precise Medicine
Current Topics in Medicinal Chemistry Transferrin Coupled Liposomes for Enhanced Brain Delivery of Doxorubicin
Vascular Disease Prevention (Discontinued) Apoptotic Signaling in Pancreatic Cancer – Therapeutic Application (Supplemental Data)
Current Cancer Therapy Reviews Role of C1QBP/p32 and its Therapeutic Potential in Breast Carcinoma and other Cancers
Current Medicinal Chemistry The Role of PET/CT and SPECT/CT in Oncology Drug Development
Current Molecular Imaging (Discontinued) Obesity and Inflammation: Colorectal Cancer Engines
Current Molecular Pharmacology Iron Oxide Nanoparticles Synthesized Via Green Tea Extract for Doxorubicin Delivery
Current Nanoscience Heat Shock Proteins in Cancer: Signaling Pathways, Tumor Markers and Molecular Targets in Liver Malignancy
Protein & Peptide Letters Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment
Current Topics in Medicinal Chemistry Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Anti-Cancer Agents in Medicinal Chemistry Combined Treatment with JFKD and Gefitinib Overcomes Drug Resistance in Non-Small Cell Lung Cancer
Current Pharmaceutical Biotechnology Therapeutic Gene Products Delivery by Neuron Stem Cells
Current Pharmaceutical Biotechnology Flavonoids in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry New Perspective on the Dual Functions of Indirubins in Cancer Therapy and Neuroprotection
Anti-Cancer Agents in Medicinal Chemistry Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment
Current Cancer Drug Targets Combination of Phytochemicals as Adjuvants for Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery